title: The importance of sustained blood pressure control.
abstract: The case for antihypertensive drug regimens that produce consistent 24-h blood pressure control has largely been founded upon a series of epidemiological observations that were either cross-sectional or alternatively relatively small-scale follow-up studies. More recent data have unequivocally demonstrated, in a prospective study in hypertensive subjects with left ventricular hypertrophy, that the reduction in left ventricular mass index during the course of one year's antihypertensive treatment, was predicted much more closely by treatment-induced changes in ambulatory blood pressure than by changes in clinic blood pressure. This provides definitive and confirmatory data to support the aim of achieving blood pressure control, which is based upon a smooth and consistent antihypertensive effect over a full 24-h dosage interval. Regimens which provide such control may also offer the advantage of a sustained duration of effect beyond 24 h. This characteristic is attractive because even the most compliant patient may inadvertently miss at least one dose of medication each week. Evidence from a number of studies which have sought to mimic this pattern of suboptimal compliance by deliberately inserting a placebo phase into a steady-state treatment regimen, has clearly demonstrated the benefits of antihypertensive drugs with intrinsically long duration of action. Furthermore, there is evidence to suggest that following cessation of therapy there is a biphasic reversion of blood pressure towards baseline levels with a maintenance of a residual effect which is more pronounced with a long-acting agent when compared to a shorter-acting drug from the same therapeutic class. There is increasing evidence, albeit not derived from prospective outcome studies, that indicates that the benefits of antihypertensive therapy are likely to be maximized by treatment regimens which result in sustained blood pressure control.
authors.affiliation: Department of Medicine & Therapeutics, Gardiner Institute, Western Infirmary, Glasgow, UK.
authors.forename: P A
authors.initials: PA
authors.lastname: Meredith
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage*; D000959:Antihypertensive Agents / Q000008:administration & dosage*; D018660:Blood Pressure Monitoring, Ambulatory; D004359:Drug Therapy, Combination; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D010349:Patient Compliance; D013997:Time Factors
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents